These Biotech Stocks Can Net Triple-Digit Returns Thanks to New Patents

Article was originally posted here

Unfortunately, the big pharmaceutical companies have found a way to “game” the system.

To keep competition out – and drug prices sky-high – they repeatedly make false claims of “newness.”

In fact, a recent study at the University of California School of Law showed how big of a problem this really is.

The study found that on average, 78% of drugs associated with new patents were not new drugs coming on the market, but existing drugs.

You read that right.

Nearly eight in 10 drug patents are not going to new drugs.

They’re old drugs getting new patents.

And according to this same study, half of these patents were extended multiple times.

That means American patients are paying through the nose because of this patent-rigging scheme.

Editor’s Note: This situation is so potentially lucrative, even a small stake could double, quadruple, or even net you eight times your money – in as little as two months. Take a closer look here

These crooked loopholes drive billions of dollars of profit…

And they also prevent off-patent drugs from reaching Americans at a fraction of the cost.

On top of that, the FDA simply wasn’t approving these drugs fast enough.

Fortunately, there’s a way you can fight back and profit along the way…

How You Could Net Triple-Digit Gains in the Next 12 Weeks

Nearly every time a brand-name drug loses its patent, a smaller pharmaceutical company swoops in and sees its stock skyrocket.

And a handful of smart investors double their money… quadruple their money… or even make eight times their money in a few short months.

Do these investments have risk? Of course they do. History is never guaranteed to repeat it itself.

But what makes these opportunities so great is the frequency with which they soar after taking over a patented drug…

And how little you need to invest to make a lot of money on them.

In fact, these tiny off-patent drug companies are so potentially lucrative, even a small stake could double, quadruple, or even net you eight times your money.

Up until now, these opportunities have been very hard to identify.

That’s because big drug companies – companies that already made billions in profits – continually game the system and extend their patents.

So you never really knew when the patents were going to expire or if the FDA would likely approve a generic.

Now, thanks to the American Patients First blueprint, this game is over.

Don’t Miss Michael’s Next Potential Triple-Digit Win

Michael’s paid-up Radical Technology Profits subscribers just had the chance to book a 400% gain on a cutting-edge “fintech” firm placing itself at the vanguard of cryptocurrency-based transactions.

That massive win comes less than a week after subscribers saw a 106% gain on an aggressive mid-cap biotech.

If you missed out on these profits, there’s still time to get in on the next moneymaking opportunity: a tiny $6 million company poised to remake medicine as we know it.

With 40 registered patents and 500 patents pending, it’s positioned to disrupt every aspect of the $3 trillion healthcare market. And now a shocking verdict in a bitter court battle could trigger a 28,700% sales surge.

To get all the details – and to learn how you can get all of Michael’s recommendations – click here now

Follow Money Morning on FacebookTwitter, and LinkedIn.

About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and visitors become smarter, more confident investors.To get full access to all Money Morning content, click here.

Disclaimer: © 2018 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201.

This post is from MoneyMorning. We encourage our readers to continue reading the full article from the original source here.